Empirical studies with humans suggest that selective serotonin reuptake inhibitors (SSRIs) may, through increases in serotonergic activity [1], increase insulin secretion [2], increase insulin sensitivity [3], and lower serum glucose levels [1]. Indeed, the potentially beneficial effects of SSRI treatment in diabetics are documented. However, we describe the case of a female, with diet-controlled, type 2 diabetes, whose glucose levels increased with exposure to sertraline.
GoodnickPJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Annals of Clinical Psychiatry2001;13:31–41.
2.
GomezR. Plasma insulin levels are increased by sertraline in rats under oral glucose overload. Brazilean Journal of Medical and Biological Research2001;34:1569–1572.
3.
ScheenAJLefebvrePJ. Pharmacological treatment of the obese diabetic patient. Diabete & Metabolisme1993;19:547–559.
4.
YamadaJSugimotoYInoueK. Selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms. European Journal of Pharmacology1999;382:211–215.
